Fernandes‐Charpiot 2014.

Methods	Design: open‐label RCT Duration: not reported Follow up: 12 months
Participants	Setting: single centre transplant service Country: Brazil Kidney transplant recipients of extended criteria or standard criteria DD kidneys Number (group 1/group 2): 68 (33/35) Mean age ± SD (years): not reported Sex (M/F): not reported Exclusions: not reported
Interventions	Treatment group 1 (EVL/MPS) EVL: doses not reported MPS: doses not reported Treatment group 2 (TAC/MPS) TAC: doses not reported MPS: doses not reported Co‐interventions IL2 Steroids
Outcomes	Death (all causes) Graft loss Acute rejection CMV
Notes	Comparison: TOR‐1 versus CNI Abstract only available
Risk of bias
Bias	Authors' judgement	Support for judgement
Random sequence generation (selection bias)	Unclear risk	Said to be randomised but no details provided
Allocation concealment (selection bias)	Unclear risk	Said to be randomised but no information provided
Blinding of participants and personnel (performance bias) All outcomes	High risk	Open‐label study
Blinding of outcome assessment (detection bias) All outcomes	Low risk	Primary outcomes unlikely to be influenced by lack of blinding
Incomplete outcome data (attrition bias) All outcomes	Unclear risk	Insufficient information to permit judgement ‐ abstract only
Selective reporting (reporting bias)	Unclear risk	Insufficient information to permit judgement ‐ abstract only
Other bias	High risk	Novartis Research Support listed in disclosures